2023年Graves病管理临床实践模式国际调查:十年变迁
一项全球内分泌科医生在线调查,共1252名来自85个国家的受访者参与,评估Graves病诊断、监测和治疗的变化。结果显示无并发症Graves病首选抗甲状腺药物者占91.5%,放射性碘治疗占7%,甲状腺切除术占1.5%;放射性碘作为一线选择在所有地理区域均下降,美国从1990年的69%降至2023年的11.1%。
要点
- 无并发症Graves病首选治疗:抗甲状腺药物91.5%,放射性碘7%,甲状腺切除术1.5%。
- 放射性碘作为一线选择在所有地理区域下降,美国从1990年69%降至2023年11.1%。
- 持续TRAb阳性18个月后68.7%受访者继续抗甲状腺药物;复发后59.9%选择重启抗甲状腺药物。
核心结论
- 无并发症Graves病及其变异型的管理以及持续性和复发性甲状腺功能亢进的处理已发生范式转变。
研究设计与样本
- 采用全球在线调查,纳入来自85个国家的1252名内分泌科医生,评估典型Graves病患者的诊断、监测和治疗变化以及5种不同临床场景的治疗差异。
主要发现
- 无并发症Graves病首选抗甲状腺药物者占91.5%,放射性碘治疗占7%,甲状腺切除术占1.5%。
- 与既往调查相比,放射性碘作为一线选择在所有地理区域均下降;美国从1990年的69%降至2023年的11.1%。
- 持续TRAb阳性18个月后,68.7%受访者继续使用抗甲状腺药物;复发后59.9%选择重启抗甲状腺药物。
- 活动性甲状腺眼病患者中抗甲状腺药物为首选(67.5%),甲状腺切除术为第二选择(22.9%);计划妊娠者中抗甲状腺药物为首选(72.8%),甲状腺切除术为第二选择(15.6%)。
关键数值与推荐
- 无并发症Graves病首选治疗:抗甲状腺药物91.5%,放射性碘7%,甲状腺切除术1.5%。
- 美国放射性碘作为初始治疗的比例从1990年的69%降至2023年的11.1%。
- 持续TRAb阳性18个月后继续抗甲状腺药物者占68.7%;复发后重启抗甲状腺药物者占59.9%。
- 活动性甲状腺眼病首选抗甲状腺药物67.5%,甲状腺切除术22.9%;计划妊娠首选抗甲状腺药物72.8%,甲状腺切除术15.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Over the past several decades, there have been indications of potential shifts in the diagnostic strategies, treatment, and monitoring of patients with Graves disease (GD). OBJECTIVE: To evaluate current practices in managing GD and compare them to previous surveys. METHODS: We used a global online survey of endocrinologists to assess shifts in the diagnosis, monitoring, and treatment in a typical patient with GD, as well as treatment variation in 5 different clinical scenarios. RESULTS: A total of 1252 respondents from 85 countries completed the survey. Methods used to diagnose an uncomplicated GD case have changed over the past decade, reflecting increased use of thyrotropin receptor antibody (TRAb) and reciprocal decreases in nuclear medicine studies. The preferred mode of therapy for uncomplicated GD was antithyroid drugs (ATDs) by 91.5% of respondents, radioactive iodine (RAI) therapy by 7%, and thyroidectomy by 1.5%. Compared with previous surveys, the use of RAI as a first-line choice decreased in all geographic regions. The United States had the sharpest decline in the selection of initial therapy with RAI, decreasing from 69% in 1990 to 11.1% in 2023. In patients with persistent TRAb positivity after 18 months, 68.7% of respondents would continue the use of ATDs. After a relapse of GD, resumption of ATDs was selected by 59.9% of respondents. In patients with active thyroid eye disease or planning pregnancy, ATDs were the first choice (67.5% and 72.8%, respectively), and thyroidectomy emerged as the second choice (22.9% and 15.6%, respectively). CONCLUSION: Paradigm shifts have occurred in the management of uncomplicated GD and its variants, as well as the response to persistent and recurrent hyperthyroidism.
引用
- Villagelin D, Cooper DS, Burch HB, et al. A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change. J Clin Endocrinol Metab. 2024. PMID: 38577717. doi:10.1210/clinem/dgae222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。